Literature DB >> 15231437

Placebo mechanisms and reward circuitry: clues from Parkinson's disease.

Raúl de la Fuente-Fernández1, Michael Schulzer, A Jon Stoessl.   

Abstract

Recent evidence indicates that the placebo effect in Parkinson's disease is mediated by the release of dopamine in the dorsal striatum. Interestingly, there is also placebo-induced dopamine release in the ventral striatum, which establishes a connection between the placebo effect and reward mechanisms. Specifically, we propose that placebo responses are related to the activation of the reward circuitry. Here, the clinical benefit induced by placebos represents the reward. The magnitude of the placebo effect likely depends on the a priori probability of clinical benefit. This notion has profound implications in the design of clinical trials and placebo investigations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15231437     DOI: 10.1016/j.biopsych.2003.11.019

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  23 in total

1.  Therapeutic application of transcranial magnetic stimulation in Parkinson's disease: the contribution of expectation.

Authors:  Antonio P Strafella; Ji Hyun Ko; Oury Monchi
Journal:  Neuroimage       Date:  2006-03-20       Impact factor: 6.556

2.  Perceptions of a Videogame-Based Dance Exercise Program Among Individuals with Parkinson's Disease.

Authors:  Lauren R Natbony; Audra Zimmer; Larry S Ivanco; Stephanie A Studenski; Samay Jain
Journal:  Games Health J       Date:  2013-08

3.  Amygdala subregions tied to SSRI and placebo response in patients with social anxiety disorder.

Authors:  Vanda Faria; Lieuwe Appel; Fredrik Åhs; Clas Linnman; Anna Pissiota; Örjan Frans; Massimo Bani; Paolo Bettica; Emilio M Pich; Eva Jacobsson; Kurt Wahlstedt; Mats Fredrikson; Tomas Furmark
Journal:  Neuropsychopharmacology       Date:  2012-05-23       Impact factor: 7.853

4.  Failure of Placebo Analgesia Model in Rats with Inflammatory Pain.

Authors:  Xiang-Sha Yin; Jin-Yu Yang; Shuai Cao; Yun Wang
Journal:  Neurosci Bull       Date:  2019-08-21       Impact factor: 5.203

5.  Genetic biomarkers of placebo response: what could it mean for future trial design?

Authors:  Kathryn T Hall; Ted J Kaptchuk
Journal:  Clin Investig (Lond)       Date:  2013-04-01

6.  Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson's disease patients with wearing-off: efficacy, safety and feasibility--an open-label, 6-week study.

Authors:  Karla Eggert; Orjan Skogar; Khaled Amar; Liisa Luotonen; Mikko Kuoppamäki; Mika Leinonen; Helena Nissinen; Wolfgang Oertel
Journal:  J Neural Transm (Vienna)       Date:  2009-12-15       Impact factor: 3.575

Review 7.  The dopaminergic basis of human behaviors: A review of molecular imaging studies.

Authors:  Alice Egerton; Mitul A Mehta; Andrew J Montgomery; Julia M Lappin; Oliver D Howes; Suzanne J Reeves; Vincent J Cunningham; Paul M Grasby
Journal:  Neurosci Biobehav Rev       Date:  2009-05-27       Impact factor: 8.989

Review 8.  Mechanisms of the placebo effect in pain and psychiatric disorders.

Authors:  R D Holmes; A K Tiwari; J L Kennedy
Journal:  Pharmacogenomics J       Date:  2016-03-22       Impact factor: 3.550

9.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

10.  Are we drawing the right conclusions from randomised placebo-controlled trials? A post-hoc analysis of data from a randomised controlled trial.

Authors:  M Diana van Die; Kerry M Bone; Henry G Burger; Helena J Teede
Journal:  BMC Med Res Methodol       Date:  2009-06-23       Impact factor: 4.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.